Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

For years now Roche has dom­i­nat­ed the very top cir­cle of Big Phar­ma R&D, in­vest­ing more than $8 bil­lion a year in drug de­vel­op­ment through a glob­al net­work of re­search cen­ters con­cen­trat­ed at Chugai, gRED in South San Fran­cis­co and pRED out of Basel. And as far as CEO Sev­erin Schwan is con­cerned, that’s a win­ning for­mu­la that he has no plans to tam­per with, even as Roche digs in­to its vast R&D ops in search of some greater ef­fi­cien­cies.

Tim An­der­son

That’s one of the bot­tom lines in an in-depth re­port by Bern­stein an­a­lyst Tim An­der­son af­ter a re­cent sit-down with Schwan, of­fer­ing a chance to do a deep dive in­to the Roche chief’s think­ing on port­fo­lio strat­e­gy, top-line growth and R&D. The dis­cus­sion cen­ters on the CEO’s suc­cess­ful strat­e­gy of gain­ing mar­ket­ing ap­proval for a new set of block­busters like Hem­li­bra as biosim­i­lars bite in­to their ag­ing fran­chise ther­a­pies. 

Roche’s Genen­tech ac­qui­si­tion re­mains one of the most in­trigu­ing M&A suc­cess sto­ries in bio­phar­ma. Genen­tech has con­tin­ued to pro­duce block­buster drugs years af­ter some an­a­lysts would have ex­pect­ed the in­no­v­a­tive juices to have dried up. Schwan at­trib­ut­es their suc­cess to pre­serv­ing their “struc­ture, cul­ture, and in­fra­struc­ture around Genen­tech” while in­te­grat­ing every­thing out­side of R&D. 

So what about an R&D in­te­gra­tion now? “Over my dead body,” replies the CEO. But that doesn’t mean Schwan has stopped look­ing for ways to carve costs out of the re­search and de­vel­op­ment groups.

There are ar­eas where he con­cedes ROG is not very pro­duc­tive, for ex­am­ple, da­ta man­age­ment. ROG is build­ing da­ta sets that share com­mon sys­tems across busi­ness units, where there’s not on­ly an ef­fi­cien­cy el­e­ment, but al­so a pro­duc­tiv­i­ty el­e­ment when you can bet­ter share da­ta. ROG has talked a lot about lever­ag­ing re­al-world da­ta, but it starts with shar­ing your own da­ta from your own clin­i­cal tri­als too. So, they’re do­ing both in par­al­lel.

Back of­fice func­tions and man­u­fac­tur­ing are two key ar­eas where Roche plans to do some cost cut­ting. And their adop­tion of new tri­al de­sign strate­gies al­so of­fers a shot at greater ef­fi­cien­cy.

He thinks de­vel­op­ment is an area where in­tel­li­gent tri­al de­sign can im­prove both ef­fi­cien­cy and pro­duc­tiv­i­ty, lever­ag­ing re­al-world da­ta in a very dif­fer­ent way. Dr. Schwan thinks there’s a lot of po­ten­tial here to in­flu­ence how ROG works with reg­u­la­tors around the world. So, he sees sub­stan­tial pro­duc­tiv­i­ty op­por­tu­ni­ties across the val­ue chain, par­tic­u­lar­ly with­in man­u­fac­tur­ing and de­vel­op­ment.

It’s al­so in­ter­est­ing to see how Schwan sees the com­pa­ny’s po­si­tion in the im­muno-on­col­o­gy field, where he frankly sees Roche be­hind two key lead­ers as Bris­tol-My­ers Squibb and Mer­ck switch places on the num­ber 1 and num­ber 2 po­si­tions. For the CEO, I/O now is on track, with Tecen­triq mak­ing it to the mar­ket in seg­ments of the mar­ket with lim­it­ed op­por­tu­ni­ties. That was the first of three big waves he’s track­ing.

Here’s An­der­son’s sum­ma­ry:

Tecen­triq has pret­ty much achieved what ROG set out to do in this first wave. The sec­ond wave is about com­bi­na­tion strate­gies with Tecen­triq. Dr. Schwan ap­pre­ci­ates the cred­it for chemo com­bo, and we’ve seen that play out well for com­pa­nies that as­cribed to this ap­proach. He ad­mits Keytru­da cer­tain­ly has an ad­van­tage here since they’re al­ready on the mar­ket and ap­proved in 1L lung, and have pos­i­tive re­sults from KN-189 in-hand. ROG is in catch up mode, but still in the race, par­tic­u­lar­ly with IM­pow­er 130, which he views as more com­pa­ra­ble to MRK’s da­ta set. IM­pow­er 150 is a com­plete­ly dif­fer­ent reg­i­men that works bet­ter in cer­tain cas­es than oth­ers. Of course, there’s al­so IM­pow­er 132, which is near-term and very im­por­tant. Yes, Keytru­da is ahead, but de­pend­ing on how var­i­ous tri­als read out, ROG could be back in the game, par­tic­u­lar­ly with IM­pow­er 132. He al­so high­lights the TNBC op­por­tu­ni­ty with Tecen­triq, but views this as a high­er risk ven­ture, rep­re­sent­ing an up­side case. In the third wave of I/O, he thinks the breadth and depth of ROG’s pipeline po­si­tions them as one of, if not, the leader. So, to­day, MRK is no doubt ahead, but he thinks the ju­ry is still out on lung can­cer, and we’ll have to wait and see how the sto­ry with next-gen­er­a­tion nov­el I/O mol­e­cules un­fold.


Im­age: Sev­erin Schwan. ROCHE

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.